Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement
| Autor: | Marcie Fisher-Borne, Robert A. Smith, Elizabeth T. H. Fontham, Kristina E. Lam, Lacey Loomer, Kimberly S. Andrews, Debbie Saslow, Deana Manassaram-Baptiste |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Gynecology
medicine.medical_specialty education.field_of_study Cancer prevention business.industry Population Alternative medicine Cancer Hematology Guideline medicine.disease Vaccination 03 medical and health sciences Papillomavirus Vaccines 0302 clinical medicine Oncology Immunization 030225 pediatrics Family medicine medicine 030212 general & internal medicine business education |
| Zdroj: | CA: A Cancer Journal for Clinicians. 66:375-385 |
| ISSN: | 0007-9235 |
| DOI: | 10.3322/caac.21355 |
| Popis: | Answer questions and earn CME/CNE The American Cancer Society (ACS) reviewed and updated its guideline on human papillomavirus (HPV) vaccination based on a methodologic and content review of the Advisory Committee on Immunization Practices (ACIP) HPV vaccination recommendations. A literature review was performed to supplement the evidence considered by the ACIP and to address new vaccine formulations and recommendations as well as new data on population outcomes since publication of the 2007 ACS guideline. The ACS Guideline Development Group determined that the evidence supports ACS endorsement of the ACIP recommendations, with one qualifying statement related to late vaccination. The ACS recommends vaccination of all children at ages 11 and 12 years to protect against HPV infections that lead to several cancers and precancers. Late vaccination for those not vaccinated at the recommended ages should be completed as soon as possible, and individuals should be informed that vaccination may not be effective at older ages. CA Cancer J Clin 2016;66:375-385. © 2016 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text